BFRI Stock Forecast: Biofrontera, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Biofrontera, Inc. is $3. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 66 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Biofrontera, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BFRI stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BFRI, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 19 May 2026 | Benchmark | Downgrade | Speculative Buy | $3.00 |
| 19 May 2025 | Benchmark | Maintains | Buy | — |
| 15 Nov 2024 | Benchmark | Reiterates | Buy | — |
| 16 Aug 2024 | Benchmark | Reiterates | Buy | — |
| 31 Aug 2023 | Benchmark | Reiterates | Buy | — |
| 5 July 2023 | Benchmark | Maintains | Buy | $140 → $18 |
| 15 May 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 9 Mar 2023 | Benchmark | Reiterates | Buy | $7.00 |
| 31 Jan 2023 | Benchmark | Reiterates | Buy | $11 → $7.00 |
| 15 Dec 2021 | Benchmark | Initiates | Buy | $11 |
| 24 Nov 2021 | Roth Capital | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BFRI.
This page is one stock. Monday covers all of them.
BFRI appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BFRI vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Biofrontera, Inc. returned −29.7% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BFRI analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 0.2×
- Price / book
- 1.2×
- EV / EBITDA
- —
Cheaper than 90% of US stocks
Cheaper than 66% of US stocks
- Revenue growth (YoY)
- 29.8%
- Earnings growth (YoY)
- —
- Gross margin
- 79.9%
- Operating margin
- −12.6%
- Net margin
- −12.7%
Higher than 78% of US stocks
Higher than 91% of US stocks
Higher than 25% of US stocks
Higher than 19% of US stocks
- Return on equity
- −100.5%
- Return on assets
- −20.6%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 19% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biofrontera, Inc. has a market value of $9.5M and an enterprise value of $13.8M.
Revenue in the twelve months to 30 June 2026: $46.2M. The latest quarter grew 32.9% year on year.
Net income over the same four quarters: −$6.4M, a −13.8% net margin.
Diluted earnings per share, trailing twelve months: −$0.60.
Free cash flow in the twelve months to 30 June 2026: −$7.9M.
forward P/E: 1.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Biofrontera, Inc. employs 84 people — $550K of revenue per employee.
Data provided by Twelve Data
BFRI and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BFRI’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Biofrontera, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BFRI
What is the BFRI stock price forecast for 2026-2027?
The median 12-month analyst price target for Biofrontera, Inc. is $3. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BFRI stock a buy right now?
Of the 1 analyst covering Biofrontera, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biofrontera, Inc. 66 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BFRI?
As at 21 Nov 2026, Biofrontera, Inc. ranks 66 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will BFRI stock go up?
No one can know that. What the data says: the median 12-month target from 1 analyst is $3, and Ticker Nerd's factor model ranks Biofrontera, Inc. 66 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BFRI stock forecast for 2030?
No analyst covering Biofrontera, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BFRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $3 over the next 12 months.
How has BFRI stock performed over the past year?
Biofrontera, Inc. returned -29.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Biofrontera, Inc. do?
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy. Its commercial portfolio centers on Ameluz, a prescription topical gel used together with BF-RhodoLED and RhodoLED lamp systems for the treatment of actinic keratoses, a common precancerous skin condition.
About Biofrontera, Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company focused on dermatology products with an emphasis on photodynamic therapy. Its commercial portfolio centers on Ameluz, a prescription topical gel used together with BF-RhodoLED and RhodoLED lamp systems for the treatment of actinic keratoses, a common precancerous skin condition. The company also markets Xepi, a topical antibiotic for impetigo, expanding its presence in prescription skin care. Biofrontera works directly with dermatology practices and specialist groups, supporting clinical use through products designed for office-based treatment settings. Headquartered in Woburn, Massachusetts, Biofrontera plays a niche role in the dermatology market by combining drug and device-based therapies for targeted skin treatment.
CEO Dr. Hermann Luebbert Ph.D. · 84 employees · United States · https://www.biofrontera-us.com